Fragment-based discovery of a highly potent, orally bioavailable ERK1/2 inhibitor that modulates the phosphorylation and catalytic activity of ERK1/2

被引：0

作者：

Heightman, Tom D. ^{[1
]}

Berdini, Valerio ^{[1
]}

Braithwaite, Hannah ^{[1
]}

Buck, Ildiko ^{[1
]}

Cassidy, Megan ^{[1
]}

Castro, Juan ^{[1
]}

Courtin, Aurelie ^{[1
]}

Day, James ^{[1
]}

East, Charlotte ^{[1
]}

Fazal, Lynsey ^{[1
]}

Graham, Brent ^{[1
]}

Griffiths-Jones, Charlotte ^{[1
]}

Lyons, John ^{[1
]}

Martins, Vanessa ^{[1
]}

Muench, Sandra ^{[1
]}

Munck, Joanne ^{[1
]}

Norton, David ^{[1
]}

O'Reilly, Marc ^{[1
]}

Palmer, Nick ^{[1
]}

Pathuri, Puja ^{[1
]}

Reader, Mike ^{[1
]}

Rees, David ^{[1
]}

Rich, Sharna ^{[1
]}

Richardson, Caroline ^{[1
]}

Saini, Harpreet ^{[1
]}

Thompson, Neil ^{[1
]}

Wallis, Nicola ^{[1
]}

Walton, Hugh ^{[1
]}

Wilsher, Nicola ^{[1
]}

Woolford, Alison ^{[1
]}

Murray, Chris ^{[1
]}

机构：

[1] Astex Pharmaceut Inc, Cambridge, England

来源：

MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期

关键词：

D O I：

10.1158/1535-7163.TARG-17-B161

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B161

引用

页数：2

共 50 条

[1] Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Heightman, Tom D.
Berdini, Valerio
Braithwaite, Hannah
Buck, Ildiko M.
Cassidy, Megan
Castro, Juan
Courtin, Aurelie
Day, James E. H.
East, Charlotte
Fazal, Lynsey
Graham, Brent
Griffiths-Jones, Charlotte M.
Lyons, John F.
Martins, Vanessa
Muench, Sandra
Munck, Joanne M.
Norton, David
O'Reilly, Marc
Palmer, Nick
Pathuri, Puja
Reader, Michael
Rees, David C.
Rich, Sharna J.
Richardson, Caroline
Saini, Harpreet
Thompson, Neil T.
Wallis, Nicola G.
Walton, Hugh
Wilsher, Nicola E.
Woolford, Alison J. -A.
Cooke, Michael
Cousin, David
Onions, Stuart
Shannon, Jonathan
Watts, John
Murray, Christopher W.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (11) : 4978 - 4992
[2] Fragment-based discovery of an orally bioavailable ERK1/2 inhibitor which reduces the level of phosphorylated ERK
Norton, David
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
[3] Characterization of a novel ERK1/2 inhibitor, which modulates the phosphorylation and catalytic activity of ERK1/2
Munck, Joanne M.
Berdini, Valerio
Bevan, Luke D.
Braithwaite, Hannah
Buck, Ildiko M.
Cassidy, Megan
Castro, Juan
Courtin, Aurelie
Day, James E.
East, Charlotte
Fazal, Lynsey
Graham, Brent
Griffiths-Jones, Charlotte M.
Heightman, Tom D.
Hindley, Chris J.
Kidane, Birikiti
Kucia-Tran, Justyna
Lyons, John F.
Martins, Vanessa
Muench, Sandra
Murray, Chris W.
Norton, David
O'Reilly, Marc
Palmer, Nick
Pathuri, Puja
Reader, Mike
Rees, David C.
Rich, Sharna J.
Richardson, Caroline J.
Saini, Harpreet K.
Shah, Alpesh
Stanczuk, Lukas
Thompson, Neil T.
Walton, Hugh
Wilsher, Nicola E.
Woolford, Alison J.
Wallis, Nicola G.
[J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[4] Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Heightman, Tom D.
Berdini, Valerio
Bevan, Luke
Buck, Ildiko M.
Carr, Maria G.
Courtin, Aurelie
Coyle, Joseph E.
Day, James E. H.
East, Charlotte
Fazal, Lynsey
Griffiths-Jones, Charlotte M.
Howard, Steven
Kucia-Tran, Justyna
Martins, Vanessa
Muench, Sandra
Munck, Joanne M.
Norton, David
O'Reilly, Marc
Palmer, Nicholas
Pathuri, Puja
Peakman, Torren M.
Reader, Michael
Rees, David C.
Rich, Sharna J.
Shah, Alpesh
Wallis, Nicola G.
Walton, Hugh
Wilsher, Nicola E.
Woolford, Alison J-A
Cooke, Michael
Cousin, David
Onions, Stuart
Shannon, Jonathan
Watts, John
Murray, Christopher W.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (16) : 12286 - 12303
[5] Discovery of potent, orally bioavailable ERK1/2 inhibitors with isoindolin-1-one structure by structure-based drug design
Ji, Dezhong
Zhang, Lingzhi
Zhu, Qihua
Bai, Ying
Wu, Yaoyao
Xu, Yungen
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 164 : 334 - 341
[6] Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2
Ren, Li
Grina, Jonas
Moreno, David
Blake, James F.
Gaudino, John J.
Garrey, Rustam
Metcalf, Andrew T.
Burkard, Michael
Martinson, Matthew
Rasor, Kevin
Chen, Huifen
Dean, Brian
Gould, Stephen E.
Pacheco, Patricia
Shahidi-Latham, Sheerin
Yin, Jianping
West, Kristina
Wang, Weiru
Moffat, John G.
Schwarz, Jacob B.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (04) : 1976 - 1991
[7] Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitor
Flemington, Vikki
Simpson, Iain
Davies, Emma
Robinson, David
Lindsay, Nicola
Hanson, Lyndsey
Hopcroft, Philip
Tonge, Michael
Roberts, Karen
Ward, Richard
[J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[8] Development of UCT-01-097, a novel orally available ERK1/2 inhibitor for the treatment of ERK1/2 dependent cancers
O'Brien, Neil A.
McDermott, Martina S.
O'Boyle, Brendan M.
Reeves, Corey M.
Bartberger, Michael
Loson, Oliver
Chau, Kevin
Hong, Jenny J.
Jia, Weiping
Kamranpour, Naeimeh
Luo, Tong
Ayala, Raul
Madrid, Athena M.
Glaspy, John A.
Stoltz, Brian M.
Slamon, Dennis J.
[J]. CANCER RESEARCH, 2023, 83 (07)
[9] Mxi2 sustains ERK1/2 phosphorylation in the nucleus by preventing ERK1/2 binding to phosphatases
Casar, Berta
Rodriguez, Javier
Gibor, Gilad
Seger, Rony
Crespo, Piero
[J]. BIOCHEMICAL JOURNAL, 2012, 441 : 571 - 578
[10] Discovery of CC-90003: A covalent ERK1/2 inhibitor
Qiao, Li-Xin
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254

← 1 2 3 4 5 →